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Abstract 
This article reports on particle engineering by a top-down method involving the 
organic solvent-free acoustic cavitation of ibuprofen (IBU). The process parameters 
(temperature, amplitude, sonication period and stabilizers) were optimized. The particle 
size distribution of IBU was measured after sonication and compared with the raw IBU (D 
0.5=153 µm). Due to acoustic cavitation, the particle size decreased (D 0.5=25 µm), but the 
use of a stabilizer was needed for further decrease (D 0.5=11 µm). Samples sonicated with 
optimized process parameters, containing the most efficient stabilizer, were dried, their 
morphology was characterized by scanning electron microscopy and the structure was 
determined by differential scanning calorimetery and X-ray powder diffraction (XRPD). 
During the thermoanalytical and XRPD characterization, the crystalline structure of IBU 
was detected after the sonication procedure. 
 
Rezumat 
Prezentul articol se încadreazǎ în domeniul ingineriei particulelor prezentând o 
metodǎ de cavitare acusticǎ fǎrǎ solvent organic a ibuprofenului (IBU). Parametrii 
procedeului (temperaturǎ, amplitudine, timp de sonicare şi stabilizatori) au fost optimizaţi. 
Dupǎ sonicare s-a mǎsurat distribuţia mǎrimii particulelor de IBU. Datoritǎ cavitǎrii 
acustice, dimensiunea particulelor a scǎzut (D = 0.5=25 µm), dar a fost necesarǎ utilizarea 
unui stabilizator pentru o scǎdere mai pronunţatǎ (D 0.5=11 µm). Probele sonicate, cu 
parametrii de proces optimizaţi, conţinând cel mai eficient stabilizator, au fost uscate şi 
caracterizate morfologic prin microscopie de scanare electronicǎ, precum şi structural, prin 
calorimetrie de scanare diferenţialǎ şi difracţie de raze X (XRPD). În timpul analizei 
termice şi XRPD, structura cristalinǎ a IBU a fost identificatǎ dupǎ sonicare. 
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Introduction 
 Particle engineering techniques have been developed to produce 
drug particles with modified physico-chemical and biopharmaceutical 
properties. Different procedures are employed in order to optimize the habit 
of the particles [17, 15, 21]. The procedures involve either particle size 
reduction of larger crystals (top-down approach - disintegration) or the 
building-up of particles (bottom-up approach-integration) [4, 5, 3, 2]. 
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Energy input may be important for the particle size reduction of 
active substances, and is possible by cavitation [20]. Cavitation is the 
formation and immediate implosion of cavities in a liquid. Cavitation is 
usually divided into two classes: inertial and non-inertial cavitation. Inertial 
cavitation is the process where a void or bubble in a liquid rapidly collapses, 
producing a shock wave. Non-inertial cavitation is the process in which a 
bubble in a fluid is forced to oscillate in size or shape due to some form of 
energy input. In pharmaceutical technology, hydrodynamic (high-pressure 
homogenization) and acoustic (power ultrasound) cavitation, are generally 
used, which are of non-inertial cavitation type. Acoustic cavitation, a novel 
possibility to decrease particle size [2, 8, 22], has the ability to erode and 
break down particles [13]. Particle engineering uses ultrasound power in the 
frequency range 20-100 kHz to induce particle size reduction [23]. 
 Power ultrasound is used for the processing of liquids, e. g. mixing, 
emulsifying, dispersing and de-agglomeration or milling. During sonication, 
the sound waves that propagate into the liquid media result in alternating 
high-pressure and low-pressure cycles, with rates depending on the 
frequency. During the low-pressure cycle, high-intensity ultrasonic waves 
create small vacuum bubbles or voids in the liquid. If the acoustic intensity 
is sufficiently high, the bubbles will first grow in size and then rapidly 
collapse during a high-pressure cycle. This phenomenon is termed 
ultrasonic cavitation [24]. Ultrasonic liquid processing is described by a 
number of parameters (amplitude, pressure, temperature and concentrations 
of compounds). The effect of the process may be determined as a function 
of the energy per processed volume: 
 
effect = f (E/V) 
where the energy (E) is the product of the power output (P) and the duration 
of exposure (t): 
E[Ws] = P[W] * t[s] 
  The function alters with changes in the individual parameters. 
Additionally, the actual power output per surface area of the sonotrode of an 
ultrasonic unit depends on the parameters [10]. 
Ibuprofen is a non-steroidal anti-inflammatory drug, which is often 
used for the relief of symptoms of arthritis or fever, and as an analgesic [26, 
16]. We chose IBU as a model crystalline drug because of its large particle 
size (D 0.5=153.73 µm) and low melting point (approximately 75 °C) [12]. 
Formulation of the IBU-β-cyclodextrin complex [6] and amorphization of 
this drug are known as feasible ways to increase its solubility [25]. The 
rapid expansion of supercritical solutions (supercritical fluid technology) 
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[11, 19], melt emulsification [14] and the solvent diffusion method [12] are 
well known to decrease the particle size of IBU through use of an organic 
solvent, but the residual organic solvent may be a problem in the 
pharmaceutical formulation. 
 In the present work, the use of acoustic cavitation, as a novel organic 
solvent-free, static wet grinding technique in pharmaceutical technology is 
reported. The aims of our work were to reduce the particle size of IBU to 
the micrometer range by using power ultrasound, with optimization of the 
process parameters (temperature, amplitude and sonication period) and 
excipients, and to study the effects of power ultrasound on the physico-
chemical properties of IBU. 
 
Materials and Methods 
 
Materials 
IBU 2-[4-(2-methylpropyl)phenyl]propanoic acid, was purchased 
from Aldrich Chemie, Deisenhofen, Germany; PVP K-25 
(polyvinylpyrrolidone) was purchased from ISP Customer Service GmBH, 
Köln, Germany; Poloxamer 188 (polyethylene-polypropylene-glycol) was 
from BASF, Ludwigshafen, Germany; Tween 80 (Polysorbat 80; 
polyoxyethylenesorbitan-monooleate) was from Hungaropharma, Budapest, 
Hungary; and Solutol HS 15 (polyethylene glycol 15-hydroxystearate) was 
from BASF, Ludwigshafen, Germany. 
 
Methods  
Optimization of process parameters 
A power ultrasound device (Hielscher UP 200S Ultrasonic processor 
with 200 W, Germany) was applied for energy input in the sample 
preparation. The samples (suspensions containing 300 mg of pure IBU in 30 
mL of water) were sonicated at room temperature without cooling (the 
initial suspension temperature was 25°C ) and using an ice bath with 
standardized temperature at around 18°C (the initial suspension temperature 
was 18°C, the temperature of the cooling water was monitored 
continuously). A range of ultrasonic amplitudes (30%, 50% and 70%) were 
tested in order to determine the optimum amplitude via a 200 W model 
ultrasound device for 10, 20 or 30 min during the procedures (Table I) 
(Figure 1). 
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Table I 
Parameters applied during sonication 
Temperature (°C) room temperature, ice cooling 
Amplitude (%) 30, 50, 70 
Time (min) 10, 20, 30 
 
 
 
Figure 1 
Scheme of preparation 
 
Effects of stabilizers on particle size distribution 
During the content optimization, different additives were applied: 
PVP K-25, Poloxamer 188, Tween 80 and Solutol HS 15. PVP K-25 is a 
stabilizer, Poloxamer 188 is a non-ionic surfactant, Tween 80 is an 
emulsifier and solubilizer, and Solutol HS 15 is a non-ionic solubilizer. 
These may promote particle size reduction and prevent agglomeration by 
stabilizing the particles against inter-particle forces [9, 8]. When the 
influence of these stabilizers was investigated, the stabilizer was dissolved 
in water and a fixed concentration of IBU was suspended in an aqueous 
solution of the excipient. The effects of the concentration of IBU (1 and 
0.25 m/v %) on the particle size decrease were also studied (Table II). The 
concentrations of the stabilizers were determined as in previous studies: 0.5 
and 0.25 m/v % of excipients were tested [12]. 
Table II 
Applied additives, concentration of IBU and additives 
Additives PVP K-25, Poloxamer 188, Tween 80, Solutol HS 15 
Concentration (m/v %) 1, 0.25 (IBU) 
0.5, 0.25 (additive) 
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Preparation of solid products 
Suspensions prepared with the optimized parameters with efficient 
stabilizer were dried in a static bed dryer (Memmert, Germany) at 50 °C  in 
order to obtain solid products. 50 °C was chosen because of the low melting 
point of IBU, which could fuse at higher temperature. The yield of IBU was 
approximately 90%. After drying, the physico-chemical properties of the 
products were investigated. 
 
Particle size distribution and morphology 
The volume particle size distribution of raw IBU was measured by 
laser diffraction (Mastersizer 2000, Malvern Instruments Ltd, 
Worcestershire, UK) with the following parameters: 300RF lens; small 
volume dispersion unit (3000 rpm); refractive index for dispersed particles 
1.4364; refractive index for dispersion medium 1.330. Water was used as 
dispersant and the obscuration was in the range 11-16% for each 
measurement. The IBU particle size was determined immediately on the 
initial water suspension. After drying, the solid product was resuspended in 
water using an ultrasonic bath for 5 min. Water was applied as dispersion 
phase, in which the additives were dissolved, and therefore only IBU 
particles could be detected. In all cases the average size volume distribution, 
D 0.1, D 0.5, and D 0.9 were determined and evaluated. 
The shape and surface characteristics of the various samples were 
visualized by using a scanning electron microscope (Hitachi S4700, Hitachi 
Scientific Ltd., Tokyo, Japan). Briefly, the samples were sputter-coated with 
gold–palladium under an argon atmosphere, using a gold sputter module in 
a high-vacuum evaporator and the samples were examined at 15 kV and 10 
µA. The air pressure was 1.3-13.0 mPa. 
 
Structural analysis 
DSC measurements were carried out with a Mettler Toledo DSC 821e 
thermal analysis system with the STARe thermal analysis program V9.0 
(Mettler Inc., Schwerzenbach, Switzerland). Approximately 2-5 mg of pure 
drug or product was examined in the temperature range between 25 °C and 
300 °C. The heating rate was 5 °C min-1. Argon was used as carrier gas at a 
flow rate of 10 L h-1 during the DSC investigations. 
The physical state of IBU in the samples was evaluated by X-ray 
powder diffraction (XRPD). XRPD patterns were produced with an X-ray 
Diffractometer Miniflex II (Rigaku Co. Tokyo, Japan), where the tube 
anode was Cu with Kα = 1.5405 Ǻ. The pattern was collected with a tube 
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voltage of 30 kV and a tube current of 15 mA in step scan mode (4° min-1). 
The instrument was calibrated by using Si. 
 
Results and Discussion 
 
Effects of process parameters on particle size distribution  
During the procedure, the experimental parameters were first 
investigated. The amplitude, temperature and sonication time were varied 
(Table III). In the starting suspensions, the concentration of IBU (with an 
average particle size of about 154 µm) was 300 mg in 30 mL of water. For 
each sample, three parallel measurements were performed to check the 
reproducibility. 
 At room temperature, the application of an amplitude of 30, 50 or 
70% resulted in a 50% decrease in the average IBU particle size. During the 
procedure, the temperature of the suspension increased from 25 °C to 77-
85 °C. We presumed that some of the invested energy was transformed to 
heat, and the D 0.9 value was therefore increased by amplitudes of 30 and 
50% (Sample 1 and Sample 2) relative to raw IBU (Figure 2 on the left). 
The reason for these phenomena is the melting of IBU, due to the 
temperature of the system increasing to above the melting point of IBU 
(75°C). After the impaction, therefore, the sample presented large 
precipitated IBU crystals.  
For Samples 4-6, continuous ice cooling (Tcooling water = 18 °C) was 
applied. After the procedure, the temperature of the suspension was 
decreased to approximately 35 °C, which prevented the melting of IBU. 
Furthermore, the cohesive forces (which promote the aggregation of the 
particles) were lower at low temperature, and this helped achieve smaller 
particles.  Sonication with an amplitude of 30% caused a further 50% 
decrease in the average particle size. The smallest particles were produced 
by the application of an amplitude of 70%, with the largest energy 
investment, on use of an ice bath (Sample 6).  
Increase of the amplitude of sonication did not cause a significant 
alteration in the temperatures of the suspensions relative to one another at 
18 °C on ice cooling. Increasing of the duration of sonication to 20 min 
resulted in a lower size reduction than with a combination of increased 
amplitude and cooling (Figure 2). No difference in particle size was 
observed when the sonication time was increased from 20 min to 30 min. A 
sonication time of 20 min was therefore, considered to be optimum (Sample 
7 and Sample 8). 
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Consequently, the increased amplitude-due to the largest energy 
investment and decreased temperature-due to lower cohesive forces and less 
energy-transformation to heat-jointly resulted in the most effective particle 
size reduction; the best combination was sonication with an amplitude of 
70% for 20 min with ice cooling, which resulted in an average IBU particle 
size of more than 25 µm because of grinding resistance (Figure 2). 
The use of a lower concentration of active substance might be 
predicted to yield a smaller particle size after the sonication, energy is 
directed to less material and the cohesive forces are weaker. Decrease of the 
concentration of IBU (0.25 m/v%) did not cause a further particle size 
reduction (Sample 9) as compared with the results at a higher concentration 
of IBU (Figure 2), which allows formulation with a larger quantity of active 
substance. 
 
Table III 
Effects of acoustic cavitation on particle size distribution at different parameters 
 
Batch 
code 
Investi-
gated 
factor 
Amp-
litude 
% 
Starting 
temperature of 
suspension 
(°C) 
Temperature of 
suspension after 
sonication 
(°C) 
Time 
(min) 
Conc. of 
IBU 
(mg/30 
mL 
water) 
Particle size 
distribution 
(µm) 
 
D 0.5 
Raw IBU  ------- ------- ------- ------- -------  153.73  
Sample 1 
Amp. 
30 25 77.7 10 300  85.16±9.14  
Sample 2 50 25 73.7 10 300  85.35±3.85  
Sample 3 70 25 85.0 10 300  84.49±1.63  
Sample 4 
Temp. 
30 18 32.3 10 300  39.44±2.10  
Sample 5 50 18 34.5 10 300  31.92±2.63  
Sample 6 70 18 40.0 10 300  28.19±2.30  
Sample 6 
Time 
70 18 40.0 10 300  28.19±2.30  
Sample 7 70 18 40.0 20 300  25.78±2.20  
Sample 8 70 18 37.6 30 300  24.88±2.87  
Sample 7 
Conc. 
70 18 40.0 20 300  25.78±2.20  
Sample 9 70 18 37.8 20 75  22.24±5.82  
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Figure 2 
Particle size distribution of IBU after sonication under different conditions 
(Samples 1-9) 
 
Effect of stabilizers 
The choice of stabilizer is specific for each drug candidate and each 
formulation procedure. The stabilizer should exhibit sufficient affinity for 
the particle surface in order to stabilize the suspension. When the influence 
of different stabilizers was investigated, the suspensions were prepared with 
a fixed concentration of the drug and optimized parameters (see Sample 7). 
The type of compound employed for stabilization has a pronounced effect 
on the particle size and distribution (Table IV). Four different stabilizers 
were tested to check the effect of the nature of the surfactant on the IBU 
particle size. Micronized drugs have a tendency to agglomerate as a result of 
their hydrophobicity, thus reducing their available surface area [8, 1]. One 
of the most common methods to reduce the tendency to drug agglomeration 
is a steric technique. Steric stabilization is achieved by adsorbing polymers 
onto the drug particle surface [9], forming a protective layer on the surface 
of the particles and overcoming the cohesive forces. Solutol was least 
effective, followed by PVP and Tween 80. The smallest particle size was 
achieved with Poloxamer: the average size was approximately 11 µm. When 
Poloxamer was used, this stabilizer exerted a strong steric stabilization 
effect preventing aggregation of the particles. An important function of 
polymers (e. g. Poloxamer) is that they can form a substantial mechanical 
and thermodynamic barrier at the interface, which retards the approach and 
coalescence of individual emulsion droplets [7]. Non-ionic non-polymeric 
surfactants (e.g. Tween) offer an advantage over polymers in that they have 
a higher adsorption potential than an equal-chain-length polymer [18]. 
The use of a lower concentration of Poloxamer might be expected to 
lead to a large IBU particle size because it could well be less effective as 
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regards overcoming the cohesive forces. However, a decreased 
concentration of Poloxamer did not cause a particle size reduction: no 
significant change in average particle size occurred. 
 
Table IV 
Effects of additives on IBU particle size distribution 
Sample Type of additive Size 
  D 0.1 (µm) D 0.5 (µm) D 0.9 (µm) 
Sample 7 ------- 10.97±1.65 25.78±2.20 59.18±1.73 
Sample 10 0.5% PVP 5.82±0.08 12.56±0.11 24.55±1.09 
Sample 11 0.5% Tween 5.29±0.03 11.14±0.11 23.64±2.33 
Sample 12 0.5% Solutol 6.71±0.11 14.57±0.28 27.74±0.63 
Sample 13 0.5% Polox 5.13±0.23 11.09±0.03 21.47±0.62 
Sample 14 0.25% Polox 5.26±0.43 11.53±0.40 22.49±0.23 
 
 Table V lists the optimum experimental factors for the most efficient 
IBU particle size reduction. The batch containing 0.25% Poloxamer as 
stabilizer and sonicated with an amplitude of 70% for 20 min under ice 
cooling was dried in a static bed dryer at 50 °C in order to obtain a solid 
product. 
 
Table V 
Sample produced with optimized parameters using the most appropriate additive 
 Additive Amp/T 
(%)/(°) 
T (Susp) 
(°) 
Time 
(min) 
Conc. 
(mg/30 mL) 
Size 
D 0.5 (µm) 
Dried Sample 
14 
0.25% Polox. 70/ 18 35.5 20 300 11.5 
Characterization of dried product 
 
Particle size distribution and morphology 
The change in average particle size on drying was not significant as 
compared with the suspension of Sample 14: aggregation did not occur. The 
specific surface area of IBU increased 10-fold due to acoustic cavitation and 
was not altered after drying (Table VI). 
 
Table VI 
Specific surface and size distribution of pure IBU and two samples 
 Spec. surface 
(m²/g) 
D 0.1  
(µm) 
D 0.5 
(µm) 
D 0.9 
(µm) 
Raw IBU 0.062 48.50 153.73 319.36 
Sample 14 
(suspension) 
0.598 5.26 11.53 22.49 
Dried Sample 14 0.614 5.52 12.44 25.38 
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The SEM pictures (Figure 3) provided an indication of the 
morphology of the modified particles. The crystal habit of pure IBU 
changed significantly. The raw IBU consisted mainly of roundish crystals 
with a broad focal size distribution. The dried product comprised irregular-
shaped crystals with an average size of 10-15 µm. Poloxamer adsorbed 
strongly onto the surfaces of IBU particles via its poly(ethylene oxide) 
central block and formed a layer on the IBU surface after drying. The crystal 
lattice of IBU demonstrated defects and cracks, along which the crystals 
were disintegrated due to acoustic cavitation. These two factors accounted 
for the relatively rough surface. 
 
   A 
   B 
Figure 3 
SEM picture of raw IBU (A), and dried Sample 14 (B) 
 
Structure (DSC and XRPD) 
DSC was employed in order to investigate the crystallinity and the 
melting of IBU and Poloxamer in the pure forms and in the sonicated dried 
product. The DSC curve (Figure 4) of pure IBU revealed a sharp 
endothermic peak at 76.93oC, which is its melting point, confirming its 
crystalline structure. Poloxamer is a semi-crystalline additive (melting point: 
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55.84°C). The DSC curves exhibited sharp endothermic peaks of the two 
materials at 72.80°C (IBU) and 42.18°C (Poloxamer), indicating that the 
crystallinity of the drug was retained in the product. The IBU crystals in the 
product melted at a lower temperature than the melting point of pure IBU. 
This is due to the smaller particle size of IBU and the fact that the 
Poloxamer melted at a lower temperature, which promoted the melting of 
IBU. Both components melted at lower temperature in the product 
compared with melting point of pure materials. Several different materials 
alongside each other are present such as impurity of other components, 
which causes the melting of substances at lower melting points. 
 
Figure 4 
DSC curves of raw materials and of the product 
 
The XRPD pattern of pure IBU demonstrated its crystalline structure, 
as expected. The characteristic 2θ data: 6.50, 17.00 20.20 and 22.00. The 
XRPD pattern of pure Poloxamer exhibited peaks at 2θ values of 19.50 and 
22.00. The raw IBU and the sonicated dried IBU composite displayed 
similar X-ray diffraction patterns (Figure 5). This means that the crystalline 
form of the micronized IBU was not changed by the sonication and drying 
procedure.The differences in intensity of the IBU diffractogram peaks in the 
product as compared with raw IBU are due to the Poloxamer, a semi-
crystalline additive with a crystallization inhibitory effect besides its 
stabilizer effect. 
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Figure 5 
XRPD examination of IBU, Poloxamer and dried Sample 14 
 
Conclusions 
The top-down method can be applied to decrease the particle size and 
change the crystal habit, and in this way may it be useful for the formulation 
of original preparations and also to facilitate generic formulation. 
Our study has illustrated the important role of power ultrasound in 
drug formulation. Because of the small amount of the samples, this method 
is recommended in preformulation studies. Acoustic cavitation, a static 
disintegration method with optimized process parameters, involving a 
change in crystal habit, may decrease the IBU particle size to the 
micrometer range. For further particle size reduction, additives are needed. 
The most efficient combination proved to be sonication with an amplitude 
of 70% for 20 min under ice cooling, with Poloxamer 188 as a stabilizer, 
which resulted in an average particle size of approximately 11.5 µm. The 
specific surface area of IBU increased 10-fold compared to the initial 
particle size of pure drug due to the treatment. The crystallinity of the drug 
was retained in the product after the sonication and drying procedure. 
Wet grinding at a controlled temperature may be favourable in the 
grinding of materials with low melting points: the melting of the materials 
may be avoided. 
In the future, we plan to compare static sonication with dynamic 
sonication in a double-walled flow cell, which allows a continuous flow of 
the sample during sonication. 
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